Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target effects shaping long-term outcomes. For this reason...

Descripció completa

Dades bibliogràfiques

Autors principals:	Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Clinical investigation 2023-07-01
Col·lecció:	JCI Insight
Matèries:	Autoimmunity Neuroscience
Accés en línia:	https://doi.org/10.1172/jci.insight.169135
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!